

Product Monograph
Including Patient Medication Information

^{Pr}**VITRAKVI**[®]

larotrectinib capsules
25 mg and 100 mg larotrectinib (as larotrectinib sulfate)

larotrectinib oral solution
20 mg/mL larotrectinib (as larotrectinib sulfate)

Antineoplastic Agent

VITRAKVI, indicated for:

- the treatment of adult and pediatric patients with solid tumours that:

- have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory treatment options

has been issued marketing authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for VITRAKVI please refer to Health Canada's Notice of Compliance with conditions - drug products web site: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html>.

Bayer Inc.
2920 Matheson Blvd East,
Mississauga, Ontario
L4W 5R6
www.bayer.ca

Date of Authorization:
2026-08-26

Submission Control No: 302320

© 2026, Bayer Inc.

® TM see www.bayer.ca/tm-mc

What is a Notice of Compliance with Conditions (NOC/c)?

An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada.

Products authorized under Health Canada's NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to this product on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.

Recent Major Label Changes

1 Indication, 1.1 Pediatrics	2026-08
4 Dosage and Administration, 4.2 Recommended Dose and Dosage Adjustment	2026-08
7 Warnings and Precautions, Hepatic/Biliary/Pancreatic	2026-08
7 Warnings and Precautions, Neurologic	2026-08
7 Warnings and Precautions, Psychiatric	2026-08
7 Warnings and Precautions, Reproductive Health	2026-08
7 Warnings and Precautions, 7.1.3 Pediatrics	2026-08
7 Warnings and Precautions, 7.1.4 Geriatrics	2026-08

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes	2
Table of Contents	2
Part 1: Healthcare Professional Information	4
1 Indications	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 Contraindications	4
4 Dosage and Administration	4
4.1 Dosing Considerations	4
4.2 Recommended Dose and Dosage Adjustment	5
4.4 Administration	7
4.5 Missed Dose	8
5 Overdosage	8
6 Dosage Forms, Strengths, Composition, and Packaging	8
7 Warnings and Precautions	9
General	9
Hepatic/Biliary/Pancreatic	9
Neurologic	10

Psychiatric	10
Reproductive Health	11
7.1 Special Populations	11
7.1.1 Pregnancy.....	11
7.1.2 Breastfeeding	11
7.1.3 Pediatrics.....	11
7.1.4 Geriatrics	12
8 Adverse Reactions.....	12
8.1 Adverse Reaction Overview	12
8.2 Clinical Trial Adverse Reactions	12
8.2.1 Clinical Trial Adverse Reactions – Pediatrics	15
8.3. Less Common Clinical Trial Adverse Reactions	15
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	16
8.5 Post-Market Adverse Reactions.....	16
9 Drug Interactions	16
9.2 Drug Interactions Overview	16
9.4 Drug-Drug Interactions	17
9.5 Drug-Food Interactions	18
9.6 Drug-Herb Interactions	18
10 Clinical Pharmacology	19
10.1 Mechanism of Action	19
10.2 Pharmacodynamics	19
10.3 Pharmacokinetics	19
11 Storage, Stability and Disposal	21
Part 2: Scientific Information	22
13 Pharmaceutical Information.....	22
14 Clinical Trials	22
14.1 Clinical Trials by Indication.....	22
16 Non-Clinical Toxicology	34
Patient Medication Information.....	36

Part 1: Healthcare Professional Information

1 Indications

VITRAKVI (larotrectinib) is indicated for the treatment of adult and pediatric patients with solid tumours that:

- have a Neurotrophic Tyrosine Receptor Kinase (*NTRK*) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory treatment options.

This indication is approved based on overall response rate (ORR) and duration of response (DOR) in a pooled patient population in which most patients had rare tumours (see [14 Clinical Trials](#)).

Treatment with VITRAKVI should be initiated following confirmation of an *NTRK* gene fusion in a tumour specimen using a validated test (see [10.1 Mechanism of Action](#)).

VITRAKVI should only be administered under the supervision of a health professional experienced in the use of antineoplastic agents.

1.1 Pediatrics

Pediatrics (< 18 years of age): The safety and efficacy of VITRAKVI in pediatric patients 18 days and older were established based upon data from three multicenter, open-label, single-arm clinical studies (see [7.1.3 Pediatrics](#)).

1.2 Geriatrics

Geriatrics (≥ 65 years of age): The safety and efficacy of VITRAKVI in geriatric patients were established based upon data from three multicenter, open-label, single-arm clinical studies. Insufficient numbers of patients aged 65 and over were included to determine whether they respond differently from younger subjects (see [7.1.4 Geriatrics](#)).

2 Contraindications

VITRAKVI is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 Dosage Forms, Strengths, Composition, and Packaging](#).

4 Dosage and Administration

4.1 Dosing Considerations

- Confirm the presence of an *NTRK* gene fusion in a tumour specimen using a validated test prior to initiation of treatment with VITRAKVI (see [10.1 Mechanism of Action](#)).

4.2 Recommended Dose and Dosage Adjustment

Adults

The recommended dose of VITRAKVI in adults is 100 mg taken orally, twice daily (total dose of 200 mg) until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs.

Pediatrics

Dosing in pediatric patients is based on body surface area (BSA). The recommended dose of VITRAKVI in pediatric patients is 100 mg/m² taken orally, twice daily with a maximum of 100 mg per dose (maximum total dose of 200 mg) until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. For those subjects following the BSA-based dosing algorithm (mg/m²), oral solution dose volumes under 1.0 mL can be rounded to the nearest 0.1 mL. Oral solution dose volumes above 1.0 mL can be rounded to the nearest 0.5 mL.

Geriatrics

Clinical data indicate that age has no effect on the systemic exposure of larotrectinib (see [10.3 Pharmacokinetics - Geriatrics](#)). No dose adjustment is necessary in elderly patients.

Coadministration with Strong CYP3A4 Inhibitors

Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI, including grapefruit or grapefruit juice. If coadministration of a strong CYP3A4 inhibitor cannot be avoided, reduce the VITRAKVI dose by 50%. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, resume the VITRAKVI dose that was used prior to initiating the CYP3A4 inhibitor (see [9.4 Drug-Drug Interactions](#)).

Coadministration with Strong or Moderate CYP3A4 Inducers

Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. If coadministration of a strong CYP3A4 inducer cannot be avoided, double the VITRAKVI dose. Additionally, for coadministration with a moderate CYP3A4 inducer, double the VITRAKVI dose. After the inducer has been discontinued for 3 to 5 elimination half-lives, resume the VITRAKVI dose that was used prior to initiating the CYP3A4 inducer (see [9.4 Drug-Drug Interactions](#)).

Patients with Hepatic Impairment

Clinical data from a pharmacokinetic study indicate that larotrectinib exposure was increased in patients with hepatic impairment up to 3.2-fold (see [10.3 Pharmacokinetics - Hepatic Insufficiency](#)). Reduce the starting dose of VITRAKVI by 50% in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment. No dose adjustment is recommended for patients with mild (Child-Pugh A) hepatic impairment.

Patients with Renal Impairment

Clinical data from a pharmacokinetic study indicate that larotrectinib exposure was increased 1.46-fold in patients with end-stage renal disease (see [10.3 Pharmacokinetics - Renal Insufficiency](#)). No dose adjustment is required for patients with renal impairment.

Dose Modifications

For an adverse reaction $\geq$ Grade 3 not related to liver function test abnormalities, consider interrupting dosing of VITRAKVI and reevaluating regularly at least weekly. VITRAKVI can be withheld for up to 4 weeks to allow recovery to Grade 1 or back to baseline and resumed at the next dosage modification. Permanently discontinue VITRAKVI if an adverse reaction does not resolve within 4 weeks of the start of withholding the dose.

Recommended dose modifications for VITRAKVI for adverse reactions not related to liver function test abnormalities are provided in [Table 1](#).

Table 1: Recommended Dose Modification for Adverse Reactions

Dose Modification	Adult and Pediatric Patients with Body Surface Area of at Least 1.0 m²	Pediatric Patients with Body Surface Area Less Than 1.0 m²
1st Dose Modification	75 mg orally twice daily	75 mg/m ² orally twice daily
2nd Dose Modification	50 mg orally twice daily	50 mg/m ² orally twice daily
3rd Dose Modification	100 mg orally once daily	25 mg/m ² orally twice daily ^a

^a Pediatric patients on 25 mg/m² orally twice daily should remain on this dosage even if body surface area becomes greater than 1.0 m² during the treatment. Maximum dose should be 25 mg orally twice daily at the third dosage modification.

Permanently discontinue VITRAKVI in patients who are unable to tolerate VITRAKVI after three dose modifications.

For all Grade 2 adverse reactions, continued dosing may be appropriate, though close monitoring to ensure no worsening of the toxicity is advised.

Recommended dose modifications and management for liver function test abnormalities while receiving VITRAKVI are provided in [Table 2](#).

Table 2: Recommended Dosage Modifications and Management for VITRAKVI for Hepatotoxicity

Laboratory Parameter	Recommended Measures
Grade 2 ALT and/or AST (> 3 x ULN and ≤ 5 x ULN)	Conduct serial laboratory evaluations frequently after the observation of Grade 2 toxicity, until resolved, to establish whether a dose interruption or reduction is required.
Grade 3 ALT and/or AST (> 5 x ULN and ≤ 20 x ULN), with bilirubin < 2 x ULN OR Grade 4 ALT and/or AST (> 20 x ULN), with bilirubin < 2 x ULN	- Withhold VITRAKVI and monitor liver function frequently until recovery to Grade ≤ 1 or baseline. Permanently discontinue VITRAKVI if an adverse reaction does not resolve. - Therapy should only be resumed in patients where the benefit outweighs the risk. - If resumed, start at the next lower dose. - Permanently discontinue if a Grade 4 AST and/or ALT elevation occurs after resuming therapy.
ALT and/or AST ≥ 3 x ULN with bilirubin ≥ 2 x ULN	- Withhold VITRAKVI and monitor liver function frequently until recovery to Grade ≤ 1 or baseline. - Consider permanent discontinuation of VITRAKVI. - Therapy should only be resumed in patients where the benefit outweighs the risk. - If resumed, start at the next lower dose. Monitor liver function frequently upon restart. - Permanently discontinue if adverse reaction recurs after resuming therapy.

ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal

4.4 Administration

VITRAKVI is for oral use and may be administered with or without food. VITRAKVI is available as a capsule or oral solution formulation with equivalent oral bioavailability, and may be used interchangeably.

Capsule

The patient should be advised to swallow the capsule whole with water. The capsule should not be opened, chewed, or crushed.

Oral solution

Administer the oral solution by mouth or enterally by naso- or gastric- feeding tube with a dosing syringe.

4.5 Missed Dose

If a dose is missed, the patient should not take two doses at the same time to make up for a missed dose. Patients should take the next dose at the next scheduled time.

If the patient vomits after taking a dose, the patient should not take an additional dose to make up for vomiting.

5 Overdosage

There is no known antidote for VITRAKVI. The treatment of overdose with VITRAKVI should consist of general supportive measures.

In clinical trials, the highest single dose of VITRAKVI was 900 mg, which is equivalent to 9-times a single recommended dose when taken twice daily. Among 12 healthy adult subjects who received a single dose of either 700 or 900 mg VITRAKVI, adverse events reported in ≥ 2 subjects consisted of nausea, vomiting, dizziness, and headache.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6 Dosage Forms, Strengths, Composition, and Packaging

VITRAKVI (larotrectinib) is supplied as white opaque hard gelatin capsules containing 25 mg and 100 mg of larotrectinib and as oral solution containing 20 mg/mL of larotrectinib.

Capsules

The 25 mg capsules are white opaque hard gelatin capsules (size 2) with blue printing of "BAYER" cross and "25 mg" on the body of capsule. They are supplied in 75 mL bottles of 56 capsules.

The 100 mg capsules are white opaque hard gelatin capsules (size 0) with blue printing of "BAYER" cross and "100 mg" on the body of capsule. They are supplied in 120 mL bottles of 56 capsules.

Oral Solution

The 20 mg/mL oral solution is a colourless to yellow or orange or red or brownish liquid solution of strawberry flavour supplied in brown glass bottles of 50 mLs. Each carton contains two bottles.

Table 3: Dosage Forms, Strengths, and Composition

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Oral	capsule 25 mg, 100 mg	Gelatin, printing ink (shellac, FD&C Blue # 2 aluminum lake, titanium dioxide, propylene glycol, ammonia solution, dimethicone), titanium dioxide
Oral	solution 20 mg/mL	Citric acid (anhydrous), hydroxypropyl betadex, purified water, sodium benzoate, sodium citrate, strawberry flavour, sucralose

7 Warnings and Precautions

General

Excipients with known effects (oral solution only)

Each ml of VITRAKVI oral solution contains 2 mg of sodium benzoate. Sodium benzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).

Driving and Operating Machinery

Neurologic adverse events and fatigue have very commonly been reported in patients receiving VITRAKVI and may influence the patient's ability to drive and use machines. Caution patients and caretakers about driving and operating potentially hazardous machinery, until they are reasonably certain VITRAKVI therapy does not affect them adversely (see [7 Warnings and Precautions - Neurologic](#) and [7 Warnings and Precautions - Psychiatric](#)).

Hepatic/Biliary/Pancreatic

Hepatotoxicity including drug-induced liver injury (DILI) has been reported in patients taking VITRAKVI. Abnormalities of liver function tests may include increased ALT, AST, ALP and bilirubin.

Among the 444 patients who received VITRAKVI, treatment-emergent adverse events (TEAEs) of alanine transaminase (ALT) increased and aspartate transaminase (AST) increased of any grade were reported in 33% and 31% of patients, respectively. The maximum grades elevations were Grade 4 ALT increased in 4 patients (<1%), Grade 4 AST increased in 3 patients (<1%), Grade 3 ALT increased in 19 patients (4%) and Grade 3 AST increased in 16 patients (3%). The median time to onset of ALT increased was 1.7 months (range: 0 days to 21.5 months). The median time to onset of AST increased was 1.4 months (range: 0 days to 32.7 months).

ALT and AST increases leading to study drug interruption or dose modifications occurred in 29 (7%) patients and 26 (6%) patients, respectively. Transaminases increased, increased ALT, and increased AST led to permanent discontinuation of VITRAKVI in 0%, <1% and <1% of patients, respectively.

Cases of hepatotoxicity with increases in ALT and/or AST of Grade 2, 3 or Grade 4 severity and increases in bilirubin $\geq 2 \times$ ULN have been reported. The incidence of transaminase elevations was higher in pediatric compared with adult patients (see [8.2.1 Clinical Trial Adverse Reactions \(Pediatrics\)](#)).

In patients with hepatic transaminase elevations, withhold, modify dose or permanently discontinue VITRAKVI based on the severity (see [4 Dosage and Administration, Dose Modifications](#)).

Monitor for liver function including ALT, AST, ALP, and bilirubin assessments. Perform a baseline assessment of liver function, including transaminase levels, before the first dose, then every 2 weeks during the first month of treatment, then monthly for the next 6 months of treatment, then periodically during treatment. In patients who develop transaminase elevations, more frequent testing is needed (see [4 Dosage and Administration, Dose Modifications](#)).

Neurologic

Neurologic adverse reactions occurred in patients receiving VITRAKVI.

Among the 444 patients who received VITRAKVI, neurologic TEAEs of any grade occurred in 56% of patients, including Grade 3, Grade 4 and Grade 5 adverse events in 7%, 1%, and <1% of patients, respectively. Grade 5 depressed level of consciousness, brain edema, and cerebellar hemorrhage were reported in one patient each. Grade 4 encephalopathy, brain edema, seizure, hypersomnia, cerebrovascular accident, hydrocephalus and neurological decompensation were reported in one patient each. The following events were reported in more than one patient at a maximum severity of Grade 3: dizziness (<1%), paresthesia (<1%), syncope (<1%), headache (1%), balance disorder (<1%), hemiparesis (<1%), cognitive disorder (<1%), dysarthria (<1%), hydrocephalus (<1%), and spinal cord compression (<1%). The majority (70.4%) of initial neurologic adverse events occurred within the first three months of treatment (range: 0 days to 75.6 months). Dose modification (reduction) or interruptions based on neurologic toxicity of all grades occurred in 8% of patients, most commonly for dizziness (2%) (see [8.2 Clinical Trial Adverse Reactions – Neurologic/Psychiatric events](#)).

Gait disturbance was reported in 6% of patients with a maximum of Grade 3 in 1% of patients. Fifty percent of initial gait disturbance adverse events occurred within the first three months of treatment (range: 0 days to 35.9 months) and <1% of patients had their dose modified or interrupted due to gait disturbance.

Withholding, reducing, or permanently discontinuing VITRAKVI dosing should be considered, depending on the severity and persistence of these symptoms.

Psychiatric

Psychiatric adverse reactions occurred in patients receiving VITRAKVI.

Among the 444 patients who received VITRAKVI, psychiatric TEAEs of any grade occurred in 26% of patients, including Grade 3 and Grade 4 adverse events in 3%, and <1% of patients, respectively. Grade 4 depression, confusional state and suicidal attempt were reported in one patient each. The following events were reported in more than one patient at a maximum severity of Grade 3: delirium (<1%), mental status change (<1%), anxiety (<1%). The majority (65.5%) of initial psychiatric adverse events occurred within the first three months of treatment (range: 0 days to 57.3 months). Dose modification (reduction) or interruptions based on psychiatric toxicity of all grades occurred in 2% of patients, most commonly for delirium (<1%) (see [8.2 Clinical Trial Adverse Reactions – Neurologic/Psychiatric events](#)).

Withholding, reducing, or permanently discontinuing VITRAKVI dosing should be considered, depending on the severity and persistence of these symptoms.

Reproductive Health

Fertility

There are no clinical data on the effect of VITRAKVI on fertility. Non-clinical fertility studies with larotrectinib have not been conducted; however, changes to the female reproductive organs in rats were observed in a repeated-dose toxicity study. Lower fertility was noted in juvenile rats at high dose (see [16 Non-Clinical Toxicology](#)).

Contraception

Advise female patients of reproductive potential to use highly effective contraception during treatment with VITRAKVI and for at least one month after the final dose.

For males of reproductive potential with a non-pregnant female partner of child-bearing potential, advise use of highly effective contraception during treatment with VITRAKVI and for at least one month after the final dose.

7.1 Special Populations

7.1.1 Pregnancy

There are no clinical data on the use of VITRAKVI in pregnant women. In embryo-fetal development studies where pregnant rats and rabbits were dosed with larotrectinib during the period of organogenesis, malformations were observed at maternal exposures that were approximately 9- and 0.6- times, respectively, those observed at the clinical dose of 100 mg twice daily (see [16 Non-Clinical Toxicology](#)). Larotrectinib crosses the placenta in animals.

Based on its mechanism of action and non-clinical data, there may be risk of fetal harm when larotrectinib is administered to a pregnant woman (see [10.1 Mechanism of Action](#)). Advise pregnant women of the potential risk to a fetus. Females of childbearing potential should have a pregnancy test prior to starting treatment with VITRAKVI.

7.1.2 Breastfeeding

There are no data on the presence of larotrectinib in human milk, the effects of larotrectinib on the breastfed child, or the effects of larotrectinib on milk production. Because of the unknown risk of larotrectinib in nursing infants, advise a nursing woman to discontinue breastfeeding during treatment with VITRAKVI and for 1 week following the final dose.

7.1.3 Pediatrics

Among the 444 patients who received VITRAKVI, 154 (35%) were pediatric. Of these 154 patients, 31% were <1 month to < 2 years (n=47), 49% were 2 years to < 12 years (n=75), and 21% were 12 years to < 18 years (n=32). The median duration of exposure was 18.9 months (range: 0 to 99.4 months). Grade 3 or 4 neutropenia occurred more frequently in pediatric patients compared to adult patients (19% versus 2%). Three pediatric patients discontinued VITRAKVI due to an adverse reaction including Grade 3 ALT increased, nausea, and neutrophil count decreased (see [8.2.1 Clinical Trial Adverse Reactions \(Pediatrics\)](#)).

Based on a population pharmacokinetic analysis, in pediatric patients from 1 to 3 months of age, the drug exposure was 3-fold higher than in adults when using recommended doses. The clinical relevance is unknown (see [10.3 Pharmacokinetics](#)).

7.1.4 Geriatrics

Among the 444 patients who received VITRAKVI, 88 (20%) patients were ≥ 65 years of age and 25 (6%) patients were ≥ 75 years of age. Clinical studies of VITRAKVI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. The safety profile in elderly patients (≥ 65 years) was generally consistent with that seen in adult patients < 65 years of age. The TEAEs that were more frequent in patients ≥ 65 years of age (where frequency in ≥ 65 years of age is more than 5% higher than frequency in < 65 years of age) included fatigue, anemia, dizziness, gait disturbance, hyponatremia, dyspnea, decreased appetite, muscular weakness, asthenia, weight decreased, peripheral neuropathy and dysphagia.

8 Adverse Reactions

8.1 Adverse Reaction Overview

The safety of VITRAKVI was evaluated in 444 patients. Overall, 98% of patients experienced at least one TEAE. The most commonly reported TEAEs ($\geq 20\%$), in order of decreasing frequency, were ALT increased, AST increased, vomiting, anemia, cough, constipation, diarrhea, pyrexia, fatigue, nausea, and dizziness.

Grade 3 or 4 TEAEs occurred in 53% of patients. Grade 4 events ($n > 2$) included neutrophil count decreased ($n = 7$), sepsis ($n = 5$), ALT increased ($n = 4$), lymphocyte count decreased ($n = 3$), and AST increased ($n = 3$). Other Grade 4 adverse reactions included blood alkaline phosphatase increased ($n = 2$), leukocyte count decreased ($n = 2$), platelet count decreased ($n = 1$) and muscular weakness ($n = 1$). Grade 3 events ($\geq 2\%$) included anemia (8%), neutrophil count decreased (7%), weight increased (6%), ALT increased (4%), AST increased (4%), diarrhea (3%), pneumonia (3%), lymphocyte count decreased (3%), dyspnea (3%), hypokalemia (2%), hypophosphatemia (2%), pyrexia (2%), hypertension (2%), hyponatremia (2%), fatigue (2%), hypotension (2%), and hypoxia (2%). Other Grade 3 adverse reactions included gait disturbance (1%), vomiting ($< 1\%$), dizziness ($< 1\%$), myalgia ($< 1\%$), paresthesia ($< 1\%$), nausea ($< 1\%$), and constipation ($< 1\%$).

The most common serious adverse events ($\geq 2\%$) regardless of attribution included pneumonia, pyrexia, dyspnea, diarrhea, and vomiting.

Dose modification (interruption or reduction) of VITRAKVI dosage due to a TEAE occurred in 48% of patients. The most common TEAEs ($\geq 3\%$) leading to dose modification were ALT increased (7%), AST increased (6%), neutrophil count decreased (5%), pyrexia (5%), vomiting (4%), and pneumonia (3%). The majority of adverse events leading to dose modification occurred in the first three months of treatment.

Permanent discontinuation of VITRAKVI for treatment emergent adverse events occurred in 12% of patients. The TEAEs that led to discontinuation of VITRAKVI and occurred in more than one patient were increased ALT, increased AST, malignant neoplasm progression, dehydration, muscular weakness, neutrophil count decreased, pericardial effusion, and pneumonia.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. Therefore, the frequencies of adverse reactions observed in the clinical trials may not reflect frequencies observed in clinical practice and should not be compared to frequencies reported in clinical trials of another drug. The safety of VITRAKVI was evaluated in 444 patients (overall safety population) who received at least one dose of VITRAKVI in one adult dose-finding trial [Study 1 (LOXO-TRK-14001) ($n = 75$)], one single arm trial [Study 2

(NAVIGATE) (n=215)], and one pediatric trial [Study 3 (SCOUT) (n=154)]. The median time on treatment was 11.15 months (range: 0.0 month to 99.4 months). Two-hundred and eighty-two (64%) patients were exposed to VITRAKVI for ≥ 6 months and 214 (48%) patients were exposed for ≥ 1 year. The majority of patients had an unresectable or metastatic solid tumour, including metastatic (66%) and locally advanced (19%) disease extent at enrollment.

Overall, patients had a median age of 44 years (range: 0.1 year to 90 years) with 35% of patients being pediatric patients. Forty-seven percent of patients were males and 59% were white.

The majority (91%) of adult patients (18 years and older) received 100 mg VITRAKVI taken twice daily as their starting dose. Three pediatric dose levels were evaluated with 91% of pediatric patients having received a starting dose of 100 mg/m² (with a maximum of 100 mg) taken twice daily. The dose ranged from 50 mg daily to 200 mg twice daily in adults and 9.6 mg/m² twice daily to 120 mg/m² twice daily in pediatric patients.

Table 4: Treatment-Emergent Adverse Events Occurring in $\geq 10\%$ of Patients Treated with VITRAKVI (Pooled Analysis)

System Organ Class ^a	VITRAKVI n=444	
	All Grades n (%)	Grade 3-4 n (%)
General Disorders and Administrative Site Conditions		
Pyrexia	121 (27)	10 (2)
Fatigue	116 (26)	8 (2)
Edema peripheral	63 (14)	2 (<1)
Nervous System Disorders		
Dizziness	96 (22)	4 (<1)
Headache	81 (18)	5 (1)
Gastrointestinal Disorders		
Vomiting	134 (30)	5 (1)
Constipation	121 (27)	2 (<1)
Diarrhea	118 (27)	14 (3)
Nausea	112 (25)	2 (<1)
Abdominal pain	64 (14)	5 (1)
Musculoskeletal and Connective Tissue Disorders		
Arthralgia	79 (18)	5 (1)
Myalgia	82 (18)	3 (<1)
Pain in extremity	63 (14)	4 (<1)
Back pain	58 (13)	4 (<1)
Blood and Lymphatic Disorders		
Anemia	128 (29)	35 (8)
Neutrophil count decreased	76 (17)	36 (8)
Leukocyte count decreased	64 (14)	7 (2)
Lymphocyte count decreased	54 (12)	16 (4)

System Organ Class ^a	VITRAKVI n=444	
	All Grades n (%)	Grade 3-4 n (%)
Investigations		
Alanine aminotransferase increased	145 (33)	23 (5)
Aspartate aminotransferase increased	137 (31)	19 (4)
Weight increased	80 (18)	26 (6)
Blood creatinine increased	52 (12)	2 (<1)
Blood alkaline phosphate increased	45 (10)	6 (1)
Metabolism and nutrition disorders		
Decreased appetite	64 (14)	5 (1)
Hypoalbuminemia	51 (11)	2 (<1)
Respiratory, thoracic and mediastinal disorders		
Cough	129 (29)	2 (<1)
Dyspnea	69 (16)	12 (3)
Nasal congestion	47 (11)	0 (0)
Infections and infestations		
Upper respiratory tract infection	86 (19)	3 (<1)
Urinary tract infection	58 (13)	5 (1)
Nasopharyngitis	54 (12)	0 (0)
Skin and subcutaneous tissue disorders		
Rash	45 (10)	0 (0)

^a Adverse events are identified using MedDRA version 25.0 and graded according to CTCAE version 4.03.

Additional Information in Selected Adverse Reactions

Neurologic/Psychiatric events

In the overall safety database (n=444), neurologic/psychiatric TEAEs of any grade were reported in 64% of patients. Neurologic/psychiatric adverse events occurring in > 5% of patients included dizziness (22%), headache (18%), mood disorders (15%), cognitive impairment (11%), sleep disorders (12%), gait disturbance (6%), and paresthesia (6%). Mood disorders is collectively made up of the neurologic/psychiatric adverse events anxiety (5%), depression (3%), agitation (3%), irritability (2%), restlessness (1%), depressed mood (<1%), euphoric mood (<1%), fear (<1%), panic attack (<1%) and psychomotor hyperactivity (<1%), as well as the general disorder adverse event feeling jittery (<1%). Cognitive impairment is collectively made up of the adverse events memory impairment (4%), confusional state (2%), disturbance in attention (4%), delirium (1%), cognitive disorder (2%), aphasia (<1%), hallucination (1%), hallucination, visual (<1%), mental status changes (<1%), amnesia (<1%), and mental impairment (<1%). Sleep disorders is collectively made up of the adverse events insomnia (9%), somnolence (3%), and sleep disorder (<1%). Neurologic/psychiatric events were reported at a maximum severity of Grade 3 in 10% of patients and a maximum severity of Grade 4 in 2% of patients. Events led to dose modification (reduction) or interruption in 46 (10%) patients.

8.2.1 Clinical Trial Adverse Reactions – Pediatrics

Of 444 patients treated with VITRAKVI, 154 (35%) patients were pediatrics, including 47 infants and toddlers aged up to 23 months, 75 children aged 2 to 11 years, and 32 adolescents aged 12 to < 18 years. The safety profile in the pediatric population was generally consistent in the types of reported adverse events to those observed in the adult population. The majority of adverse events were Grade 1 or 2 in severity and were resolved without VITRAKVI dose modification or discontinuation.

The TEAEs that were more frequent in pediatric patients compared with adult patients regardless of attribution ($\geq 10\%$ difference) included vomiting (53% versus 18% in adults); transaminase elevations (ALT 42% versus 28%, AST 40% versus 26%); neutrophil count decreased (31% versus 10%); diarrhea (36% versus 22%); pyrexia (49% versus 16%); upper respiratory tract infection (36% versus 11%); leukocyte count decreased (22% versus 10%); nasopharyngitis (23% versus 7%); rhinitis (12% versus 1%), cough (40% versus 23%), headache (27% versus 13%), nasal congestion (18% versus 7%), COVID-19 (18% versus 6%), gastroenteritis (14% versus 2%), and viral infection (11% versus 1%).

Treatment-emergent adverse events reported in the infant and toddler subgroup (n=47) $\geq 20\%$ and at a higher incidence than in the other pediatric subgroups included vomiting (n=29), cough (n=22), diarrhea (n=25), pyrexia (n=37), ALT increased (n=24), AST increased (n=22), upper respiratory tract infection (n=24), constipation (n=17), nasopharyngitis (n=12), platelet count decreased (n=10), dermatitis diaper (n=12), rash (n=11), neutrophil count decreased (n=23); anemia (n=20), nasal congestion (n=10), blood alkaline phosphatase increased (n=10), and urinary tract infection (n=11).

Because of the single arm design of VITRAKVI clinical studies and confounding factors, differences in the incidence of adverse reactions in children versus adults should be given special attention but interpreted cautiously.

8.3. Less Common Clinical Trial Adverse Reactions

From the overall safety database (n=444), selected TEAEs reported as less common yet clinically significant in patients receiving VITRAKVI include:

Gastrointestinal disorders: dysgeusia (5%)

Nervous system disorders: peripheral neuropathy (5%).

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Clinically relevant laboratory abnormalities are shown in [Table 5](#).

Table 5: Clinically Relevant Laboratory Abnormalities

Laboratory Parameter [*] (SOC/PT)	Overall Safety Analysis Set n=444, n (%)		
	All Grades ^{**}	Grade 3	Grade 4
Chemistry			
Aspartate aminotransferase (AST) increased	317 (71)	26 (6)	4 (<1)
Alanine aminotransferase (ALT) increased	307 (69)	28 (6)	7 (2)
Hypoalbuminemia	257 (58)	12 (3)	0
Blood alkaline phosphatase increased	246 (55)	14 (3)	2 (<1)
Hematologic			
Hemoglobin decreased	332 (75)	40 (9)	0
Neutrophil count decreased	157 (35)	39 (9)	11 (2)
Leukocyte count decreased	202 (45)	11 (2)	5 (1)
Platelet count decreased	95 (21)	6 (1)	3 (<1)

* Includes laboratory abnormalities that were reported as treatment-related adverse events for at least 5% of patients. Data are based on the maximum toxicity grade reported during the study, including patients who had no change from baseline grade.

** NCI CTCAE version 4.03

8.5 Post-Market Adverse Reactions

The following adverse reaction has been identified during post-approval use of VITRAKVI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hepatobiliary Disorders: Liver Injury

9 Drug Interactions

9.2 Drug Interactions Overview

Larotrectinib is a substrate of cytochrome P450 (CYP) 3A, P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Coadministration of VITRAKVI with strong or moderate CYP3A inhibitors, P-gp and BCRP inhibitors may increase larotrectinib plasma concentrations.

Coadministration of VITRAKVI with strong or moderate CYP3A inducers and strong P-gp inducers may decrease larotrectinib plasma concentrations.

In vitro, larotrectinib is not a substrate for the transporters OAT1, OAT3, OCT1, OCT2, OATP1B1, or OATP1B3.

In vitro studies indicate that larotrectinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations. *In vitro*, larotrectinib is a metabolism-dependent

irreversible inhibitor of CYP3A4/5 (contributing to weak inhibition clinically (see [9.4 Drug-Drug Interactions](#)).

In vitro studies indicate that larotrectinib induces CYP2B6, but does not induce CYP1A2.

In vitro studies indicate that larotrectinib does not inhibit the transporters BCRP, P-gp, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, BSEP, MATE1 and MATE2-K at clinically relevant concentrations.

9.4 Drug-Drug Interactions

Table 6: Established or Potential Drug-Drug Interactions

Co-administered drug	Source of Evidence	Effect	Clinical comment
Effects of CYP3A, P-gp and BCRP Inhibitors on Larotrectinib			
Itraconazole (strong CYP3A inhibitor, and P-gp and BCRP inhibitor)	CT	Coadministration of a single 100 mg VITRAKVI dose with itraconazole increased larotrectinib C_{max} and AUC by 2.8-fold and 4.3-fold, respectively.	Avoid coadministration of strong CYP3A4 inhibitors with VITRAKVI (e.g. atazanavir, clarithromycin, itraconazole, ketoconazole, nelfinavir, ritonavir, saquinavir, voriconazole, grapefruit or grapefruit juice). If coadministration of a strong CYP3A4 inhibitor cannot be avoided, reduce the VITRAKVI dose by 50% (see 4.2 Recommended Dose and Dosage Adjustment).
Fluconazole or diltiazem (moderate CYP3A4 inhibitors)	T	Coadministration of VITRAKVI with fluconazole or diltiazem is predicted to increase larotrectinib C_{max} and AUC by 1.9-fold and 2.7-fold, respectively.	Monitor for adverse reactions more frequently and reduce the dosage based on the severity of emergent adverse reactions (see 4.2 Recommended Dose and Dosage Adjustment - Dose Modifications).
Effects of CYP3A and P-gp Inducer on Larotrectinib			
Rifampin (strong CYP3A and P-gp inducer)	CT	Coadministration of a single 100 mg VITRAKVI dose with multiple doses of rifampin decreased larotrectinib C_{max} and AUC by 71% and 81%, respectively.	Avoid coadministration of strong CYP3A4 inducers with VITRAKVI (e.g. carbamazepine, phenobarbital, phenytoin, rifabutin, or rifampin). If coadministration of a strong CYP3A4 inducer cannot be avoided, double the VITRAKVI dose (see 4.2 Recommended Dose and Dosage Adjustment).

Co-administered drug	Source of Evidence	Effect	Clinical comment
Efavirenz (moderate CYP3A4 inducer)	T	Coadministration of VITRAKVI with efavirenz is predicted to decrease C_{max} and AUC by 60% and 72%, respectively.	For coadministration with a moderate CYP3A4 inducer, double the VITRAKVI dose (see 4.2 Recommended Dose and Dosage Adjustment).
Effects of Larotrectinib on CYP3A Substrates			
Midazolam (sensitive CYP3A substrate)	CT	Coadministration of VITRAKVI (100 mg twice daily for 10 days) increased the C_{max} and AUC of midazolam 1.7-fold compared to midazolam alone.	Exercise caution with concomitant use of CYP3A substrates with narrow therapeutic range (e.g. fentanyl, cyclosporine, dihydroergotamine, pimozide, quinidine, sirolimus, or tacrolimus) in patients taking VITRAKVI. If concomitant use of these CYP3A substrates with narrow therapeutic range is required in patients taking VITRAKVI, monitor patients for increased adverse reactions; dose modification of the CYP3A substrates may be considered.

Legend: CT = Clinical Trial, T = Theoretical

Effects of Other Agents on Larotrectinib

P-gp and BCRP Inhibitors

Clinical data in healthy adult subjects indicate that coadministration of a single 100 mg VITRAKVI dose with a single dose of rifampin (a P-gp and BCRP inhibitor) increased larotrectinib C_{max} and AUC by 1.8-fold and 1.7-fold, respectively.

Gastric pH-elevating Agents

Larotrectinib has pH-dependent solubility. *In vitro* studies show that in liquid volumes relevant to the gastrointestinal tract (GI) larotrectinib at the recommended dose is fully soluble over entire pH range of the GI tract. Therefore, larotrectinib is unlikely to be affected by pH-modifying agents.

9.5 Drug-Food Interactions

Larotrectinib may be administered with or without food (see [10.3 Pharmacokinetics - Absorption](#)). Avoid grapefruit or grapefruit juice as these may also increase plasma concentrations of larotrectinib.

9.6 Drug-Herb Interactions

Avoid hypericum perforatum (a CYP3A4 inducer), also known as St. John's wort, as it may decrease plasma concentrations of larotrectinib.

10 Clinical Pharmacology

10.1 Mechanism of Action

Larotrectinib is an orally bioavailable, adenosine triphosphate (ATP)-competitive, and highly selective (only other kinase activity occurred at concentrations 100-fold higher) Tropomyosin Receptor Kinase (TRK) inhibitor. Larotrectinib targets the TRK family of proteins inclusive of TRKA, TRKB, and TRKC that are encoded by *NTRK1*, *NTRK2*, and *NTRK3* genes, respectively.

In-frame gene fusion events resulting from chromosomal rearrangements of the human genes *NTRK1*, *NTRK2*, and *NTRK3* lead to the formation of oncogenic TRK fusion proteins. These resultant novel chimeric oncogenic proteins are aberrantly expressed driving constitutive kinase activity subsequently activating downstream cell signalling pathways involved in cell proliferation and survival leading to TRK fusion cancer.

Larotrectinib demonstrated inhibition of TRK proteins and inhibition of proliferation of cell lines containing *NTRK* gene fusions in a concentration-dependent manner. In TRK fusion-driven mouse xenograft models larotrectinib treatment induced significant tumour growth inhibition.

Larotrectinib had minimal activity in cell lines with point mutations in the TRKA kinase domain, including the clinically identified acquired resistance mutation, G595R. Point mutations in the TRKC kinase domain with clinically identified acquired resistance to larotrectinib include G623R, G696A, and F617L.

10.2 Pharmacodynamics

Cardiac electrophysiology

Potential effects of larotrectinib on the QT interval were examined with the use of concentration-response modeling of the QTc data. The model was built on a single data set containing 36 healthy adult subjects receiving single doses ranging from 100 mg to 900 mg (n=6 per treatment arm receiving larotrectinib). Based on the model, larotrectinib at C_{max} did not prolong the QT interval to any clinically relevant extent.

10.3 Pharmacokinetics

Table 7 - Summary of Larotrectinib Pharmacokinetic Parameters in Adult Cancer Patients at Steady State^a

	C_{max}	T_{max} (h)	$T_{1/2}$ (h)	AUC_{0-24}	CL	Vd
100 mg BID Mean^b	914 ± 445 ng/mL	1.14 ± 1.46	2.99 ± 1.52	5410 ± 3813 ng*h/mL	57.33 ± 39,87 L/h	241.7 ± 217.92 L

Abbreviations: AUC = area under the curve; C_{max} = maximum drug concentration in plasma after dose; CL = Clearance; $T_{1/2}$ = Terminal half life; T_{max} = Time to reach C_{max} ; Vd = Volume distribution

^a steady-state is reached within 8 days

^b steady-state arithmetic mean

Absorption

VITRAKVI is available as a capsule and oral solution formulation. In healthy adult subjects, the AUC of larotrectinib in the oral solution formulation was similar to the capsule; C_{max} was 36% higher with the oral solution formulation.

The mean absolute bioavailability of larotrectinib was 34% (range: 32% to 37%) following a single 100 mg oral dose.

C_{max} and AUC in the capsule formulation were dose proportional in healthy adult subjects up to 400 mg and slightly greater than proportional at doses of 600 to 900 mg. Systemic accumulation is 1.6 fold at steady state.

Effect of Food

Larotrectinib C_{max} was reduced by approximately 35% and there was no effect on AUC in healthy subjects administered VITRAKVI after a high-fat and high-calorie meal compared to the C_{max} and AUC after overnight fasting.

Distribution

Binding of larotrectinib to human plasma proteins in vitro was approximately 70% and was independent of drug concentration. The blood-to-plasma concentration ratio was approximately 0.9.

Metabolism

Larotrectinib is metabolized predominantly by CYP3A4/5 (see [9 Drug Interactions](#)). Following oral administration of a single 100 mg dose of radiolabeled larotrectinib to healthy adult subjects, unchanged larotrectinib (19%) and O-glucuronide larotrectinib that is formed following loss of the hydroxypyrrolidine-urea moiety (26%) were the major circulating radioactive drug components in plasma.

Elimination

Following oral administration of 100 mg radiolabeled larotrectinib as an oral solution to healthy adult subjects, 58% (5% unchanged) of the administered radioactivity was recovered in feces and 39% (20% unchanged) was recovered in urine.

Special populations and conditions

Pediatrics:

Based on population pharmacokinetic analyses exposure (C_{max} and AUC) in pediatric patients (1 month to <3 months of age) at the recommended dose of 100 mg/m² with a maximum of 100 mg BID was 3-fold higher than in adults (≥18 years of age) given the dose of 100 mg BID. At the recommended dose, the C_{max} in pediatric patients (≥3 months to <12 years of age) was higher than in adults, but the AUC was similar to that in adults. For pediatric patients older than 12 years of age, the recommended dose is likely to give similar C_{max} and AUC as observed in adults.

Geriatrics:

Based on population pharmacokinetic analyses, C_{max} and AUC in patients >65 years were similar to those in younger patients (<65 years).

Sex:

Gender had no significant effect on the systemic exposure of larotrectinib based on population pharmacokinetic analyses.

Ethnic Origin:

Race had no significant effect on the systemic exposure of larotrectinib based on population pharmacokinetic analyses. Caucasians accounted for 72% of the analysis population.

Hepatic Insufficiency:

A pharmacokinetic study was conducted in subjects with mild (Child Pugh A), moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment, and in healthy adult control subjects with normal hepatic function matched for age, body mass index and sex. All subjects received a single 100 mg dose of larotrectinib. An increase in larotrectinib AUC_{0-inf} was observed in subjects with mild, moderate and severe hepatic impairment of 1.3, 2 and 3.2-fold respectively versus those with normal hepatic function. C_{max} was observed to increase slightly by 1.1, 1.1 and 1.5-fold respectively. Reduce the starting dose of VITRAKVI by 50% in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment. No dose adjustment is recommended for patients with mild (Child-Pugh A) hepatic impairment.

Renal Insufficiency:

A pharmacokinetic study was conducted in subjects with end stage renal disease requiring dialysis, and in healthy adult control subjects with normal renal function matched for age, body mass index and sex. All subjects received a single 100 mg dose of larotrectinib. An increase in larotrectinib C_{max} and AUC_{0-inf} , of 1.25 and 1.46-fold respectively was observed in renally impaired subjects versus those with normal renal function. No dose adjustment is recommended for patients with renal impairment of any severity.

Body Weight:

Body weight from 5.0 kg to 179.4 kg had no significant effect on the AUC of larotrectinib based on population pharmacokinetic analyses. The mean AUC of larotrectinib may be increased in children weighing <5.0 kg (see [10.3 Pharmacokinetics - Pediatrics](#)).

11 Storage, Stability and Disposal

Capsules

Store capsules at room temperature 15°C to 30°C.

Oral solution

Store solution refrigerated at 2°C to 8°C. Do not freeze.

Discard 30 days after first opening.


Part 2: Scientific Information

13 Pharmaceutical Information

Drug Substance

Non-proprietary name of the drug substance:	larotrectinib sulfate
Chemical name:	(3S)-N-{5-[(2R)-2-(2,5-Difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide sulfate
Molecular formula and molecular mass:	C ₂₁ H ₂₄ F ₂ N ₆ O ₆ S 526.51 g/mol

Structural formula:



Physicochemical properties:

Larotrectinib is a crystalline sulfate salt, appearing as an off-white to yellow to pinkish yellow solid. The solubility of larotrectinib sulfate is pH dependent, having > 10 mg/mL solubility below pH 1.5, ~ 2 – 3 mg/mL solubility at pH 2.5, and dropping to ~1 mg/mL above pH 3.5. Larotrectinib sulfate has only been observed as a single polymorph.

14 Clinical Trials

14.1 Clinical Trials by Indication

***NTRK* gene fusion positive solid tumours**

Three multicenter, open-label, single-arm clinical studies in patients with advanced cancer contributed patients to a pooled efficacy analysis evaluating VITRAKVI for the treatment of adult and pediatric patients with unresectable or metastatic solid tumours with a Neurotrophic Tyrosine Receptor Kinase (*NTRK*) gene fusion, as follows (see [Table 8](#)):

- 1) Phase 1 adult dose-finding study (Study 1 [LOXO-TRK-14001] [n=13];
- 2) Phase 2 adult and pediatric “basket” study (Study 2 [NAVIGATE] [n=191]); and
- 3) Phase 1/2 pediatric dose-finding/efficacy and safety study (Study 3 [SCOUT] [n=100]).

Enrollment to Study 1 and the Phase 1 portion of Study 3 was not restricted to patients with a documented *NTRK* gene fusion but patients with prospectively identified *NTRK* gene fusions were included in the pooled efficacy analysis. Patients enrolled to Study 2 were required to have tropomyosin receptor kinase (TRK) fusion cancer. All patients were required to have progressed following systemic therapy for their disease, if available, or would have required surgery with significant morbidity. Protocol amendments excluded patients with prior progression on approved or investigational kinase inhibitors with anti-TRK activity from Studies 2 and 3.

The assessment of efficacy is based on an analysis of 304 patients comprising an extended primary analysis set (ePAS) with cut-off date July 20, 2024. The ePAS includes the first 55 patients with solid tumours with an *NTRK* gene fusion who were enrolled across the three clinical studies (the primary analysis set [PAS]) plus additional patients who subsequently started treatment by January 19, 2024. Patients in the ePAS were required to have a documented *NTRK* gene fusion as determined by local testing; a non-Central Nervous System (non-CNS) primary tumour with ≥ 1 measurable lesion at baseline, per investigator assessment based on Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1 (v1.1); and to have received ≥ 1 dose of VITRAKVI.

Identification of *NTRK* gene fusions was prospectively determined in local certified laboratories primarily using next generation sequencing (NGS), in some cases, by fluorescence in situ hybridization (FISH) and by reverse transcription-polymerase chain reaction (RT-PCR) in one case.

The majority of adult patients received a starting dose of VITRAKVI of 100 mg orally twice daily and the majority of pediatric patients received VITRAKVI 100 mg/m² up to a maximum dose of 100 mg orally twice daily until unacceptable toxicity or disease progression.

Table 8: Summary of Clinical Studies Contributing Patients to the Pooled Efficacy Analysis Set (ePAS)

Study	Study Design and Patient Population	Dosing regimen	No. of Patients in the ePAS n=304 (n)	Median Age of Patients in the ePAS, year (range)	Sex of Patients in the ePAS (female / male)	Tumour Types of Patients in the ePAS
Study 1 (LOXO-TRK-14001)	- Phase 1, open-label, dose escalation and expansion study; expansion phase required tumours harbouring an <i>NTRK</i> gene fusion - Adult patients (≥ 18 years) with advanced solid tumours	Doses up to 200 mg once or twice daily	13	55.0 (28.0 – 80.0)	6/7	Salivary gland (n=3) GIST ^a (n=2) Lung, NSCLC (n=1) ^b Soft tissue sarcoma (n=2) Thyroid (n=4) Unknown primary cancer (n=1)

Study 2 (NAVIGATE)	- Phase 2 multinational, open label, tumour “basket” study - Adult and pediatric patients ≥ 12 years with advanced solid tumours harbouring an <i>NTRK</i> gene fusion	100 mg twice daily	191	57.0 (6.0-90.0)	112/79	Salivary gland (n=24) Sarcoma (n=28) Colorectal (n=26) Thyroid (n=26) ^b Melanoma (n=10) ^b Lung, NSCLC (n=29) ^b Lung, SCLC (n=1) ^b Lung, atypical carcinoid (n=1) GIST ^a (n=3) Cholangio-carcinoma (n=4) Pancreas (n=7) Breast, non-secretory (n=10) ^b Breast, secretory (n=5) Other (n=17) ^c
-------------------------------	---	--------------------	-----	--------------------	--------	--

Study 3 (SCOUT)	- Phase 1/2 multinational, open-label, dose escalation and expansion study; Phase 2 expansion cohort required advanced solid tumours harbouring an <i>NTRK</i> gene fusion - Pediatric patients from birth to 21 years	Dosing based on adult equivalent of 100 or 150 mg BID, then 100 mg/m ² twice daily (with a maximum of 100 mg twice daily)	100	2.54 (0.05-19.92)	42/58	Infantile fibrosarcoma (n=49) Soft tissue sarcoma (n=42) Bone sarcoma (n=2) Congenital mesoblastic nephroma (n=2) Melanoma (n=1) Breast, secretory (n=1) Thyroid (n=1) Lipofibromatosis (n=1) Cervix (n=1)
----------------------------	---	--	-----	----------------------	-------	--

^a GIST= gastrointestinal stromal tumour

^b Brain metastases were observed in some patients with the following tumour types: lung (non-small cell lung cancer [NSCLC], small cell lung cancer [SCLC]), thyroid, melanoma, breast (non-secretory), external auditory canal, soft tissue sarcoma and testes.

^c Other tumour types included Appendix (n=1), Bone Sarcoma (n=1), Hepatic (Hepatocellular Carcinoma) (n=1), Prostate (n=2), cervix adenocarcinoma (n=1), unknown primary cancer (n=1), duodenal (n=1), esophageal (n=1); external auditory canal (n=1), gastric (n=3), thymus (n=1), urothelial (n=1), uterus (n=1) and testes (n=1).

For the pooled efficacy analysis, the primary endpoint was overall response rate (ORR), while the duration of response (DOR) was a secondary endpoint, both determined by a blinded Independent Review Committee (IRC) according to RECIST, v1.1. Additional secondary efficacy outcomes assessed included time to first response. A lower boundary of 30% for ORR, considered to be clinically meaningful, was predefined as statistically significant for response. The ORR was defined as the proportion of patients with the best overall response of confirmed complete response (CR) or confirmed partial response (PR).

Baseline characteristics for the pooled 304 patients with solid tumours harbouring an *NTRK* gene fusion were as follows: median age 44.5 years (range 0-90 years); 33% < 18 years of age, 67% ≥ 18 years, and 21% ≥ 65 years; 55% white and 49% male; and Eastern Cooperative Oncology Group (ECOG) Performance Status (ECOG PS) 0 - 1 (88%), 2 (10%) or 3 (2%). Seventy-three percent of patients had metastatic disease and 27% of patients had locally advanced, unresectable disease. Median time from diagnosis was 1.2 years (range: 0.02-45.88 years, n=303). Ninety-one percent of patients had received prior treatment for their cancer, defined as surgery, radiotherapy, or systemic therapy. Of these, 72% had received prior systemic therapy with a median of 1 prior regimens received (range: 0-10).. Twenty-five percent of all patients had received no prior systemic therapy. Twenty-eight percent of all patients had received 1 prior systemic therapy and 47% of all patients had received 2 or more prior systemic therapies.

The most common tumour types represented were soft tissue sarcoma (24%), infantile fibrosarcoma (16%), lung cancer (11%), thyroid cancer (10%), salivary gland tumour (9%) and colorectal cancer (9%). *NTRK* gene fusions were identified by NGS, FISH, RT-PCR and other methods in 89.8%, 4.9%, 3.8% and 1.4% of patients, respectively. The TRK fusions involved *NTRK1* (in 45% of patients), *NTRK2* (in 4%), *NTRK3* (in 48%) and 67 unique upstream fusion partners. In ten patients (4%) with infantile fibrosarcoma who had a documented *ETV6* translocation identified by FISH, *NTRK3* gene fusions were inferred.

In the ePAS (n=304), with a median duration of follow-up of 45.1 months, the overall response rate (ORR) was 65% (95% confidence interval [CI]: 59, 70). The ORR included a CR in 66 patients (22%), a pathological CR (pCR) in 20 (7%), and a PR in 112 (37%). Fifty eight percent of responders (115 of 198 patients) were censored for duration of response, the majority of whom (94 of 115) were still in response. The duration of response exceeded 12 months in 80% of patients and the median duration of response (DOR) was 43.3 months (range: 0+ to 84.7+). The pooled efficacy results for overall response rate and best overall response are presented in [Table 9](#).

Table 9: Efficacy Results for Pooled Efficacy Analysis Set (ePAS) (Best Overall Response, IRC Assessment)

Efficacy Parameter	Pooled Analysis Set n=304
Overall Response Rate (ORR)^a % (n) [95% CI]	65% (198) [59, 70]
Complete Response (CR)	22% (66)
Pathological Complete Response ^b	7% (20)
Partial Response (PR)	37% (112)

IRC: Independent Review Committee


^a ORR according to RECIST 1.1

^b A pathological CR was a CR achieved by patients who were treated with larotrectinib and subsequently underwent surgical resection with no viable tumour cells and negative margins on postsurgical pathology evaluation. The pre-surgical best response for these patients was reclassified pathological CR after surgery following RECIST v1.1.

The median time to first response was 1.84 months (range: 0.89 to 22.90 months) and 74% of responses occurred within the first 2 months of treatment which coincides with the timing of the first assessment protocol. ORR in the adult sub-population (n=205) was 55% and 86% in the pediatric sub-population (n=99).

Changes in target lesion size for individual patients are illustrated in the Waterfall plot in [Figure 1](#).

Figure 1: Best percentage change from baseline in sum of diameters of target tumour lesion, in patients with NTRK fusion - IRC assessment



IRC: Independent Review Committee

Patients of the pooled analysis set with measurable disease in IRC and at least 1 post-baseline assessment (n = 265). Additional efficacy results by tumour type and by *NTRK* gene fusion partner are presented in [Table 10](#) and [Table 11](#), respectively.

Table 10: Efficacy Results by Tumour Type (IRC Assessment) for Pooled Analysis Set (ePAS)

Tumour Type	n	ORR^a % (95% CI)	DOR Range (months)	Rate (%) DOR at 12, 24, 48 months^b
Overall	304	65 (59, 70)	0.03+ to 84.67+	80, 66, 48
Soft tissue sarcoma	72	68 (56, 79)	0.03+ to 84.67+	80, 72, 53
Infantile fibrosarcoma	49	94 (83, 99)	1.58+ to 73.66+	83, 66, 57
Thyroid	31	65 (45, 81)	3.71+ to 83.94+	85, 63, 28
Salivary gland	27	85 (66, 96)	2.73+ to 81.12	91, 86, 64
Lung	32	69 (50, 84)	1.87+ to 67.22+	75, 52, 33
Colon	25	48 (28, 69)	3.88+ to 56.31+	83, 62, 31
Melanoma	11	45 (17, 77)	1.87+ to 23.20+	50, NR, NR
Breast	16	50 (25, 75)	7.43+ to 69.19+	73, 58, 58
GIST	5	80 (28, 99)	9.46 to 50.43+	75, 38, 38
Bone sarcoma	3	33 (1, 91)	9.49 ^c	0, 0, 0
Cholangiocarcinoma	4	0 (NC)	NA	NA
Pancreas	7	14 (0, 58)	5.78 ^c	0, 0, 0
Appendix	1	0 (NC)	NA	NA
Cancer of unknown primary	2	100 (16, 100)	5.59, 7.39 ^c	0, 0, 0
Congenital mesoblastic nephroma	2	100 (16, 100)	32.89+ to 44.45 ^c	100, 100, 0
Hepatic	1	0 (NC)	NA	NA
Prostate	2	0 (NC)	NA	NA
Cervix	2	50 (1, 99)	18.66+	100, NR, NR
Colorectal (Rectal)	1	0 (NC)	NA	NA
Duodenal	1	0 (NC)	NA	NA
Esophageal	1	0 (NC)	NA	NA
External auditory canal	1	100 (3%, 100%)	45.08+ ^c	100, 100, NR
Gastric	3	0 (NC)	NA	NA
Thymus	1	0 (NC)	NA	NA
Urothelial	1	0 (NC)	NA	NA
Uterus	1	0 (NC)	NA	NA
Lipofibromatosis	1	100 (3%, 100%)	17.68+ ^c	100, NR, NR
Testes	1	0 (NC)	NA	NA

CI: confidence interval; GIST: gastrointestinal stromal tumour; IRC: Independent Review Committee; NA: not

available; NC: not calculated; NR: not reached; ORR: overall response rate; + denotes ongoing

^a ORR according to RECIST 1.1

^b Estimated using Kaplan-Meier method

^c Based on a single subject

Table 11: Efficacy Results by *NTRK* Gene Fusion Partner for Pooled Efficacy Analysis Set (ePAS)

<i>NTRK</i> Gene Fusion Partner	n	ORR^a % (95% CI)	DOR Range (months)
Overall	304	65 (59, 70)	0.03+ to 84.7+
ETV6-NTRK3 including inferred	119	82 (73, 88)	0.03+ to 81.1+
TPM3-NTRK1	63	68 (55, 79)	0.8+ to 84.7+
LMNA-NTRK1	29	69 (49, 85)	3.4+ to 81.7+
TPR-NTRK1	12	58 (28, 85)	3.0+ to 55.5+
EML4-NTRK3	7	57 (18, 90)	7.9 to 46.5+
IRF2BP2-NTRK1	4	100 (40, 100)	3.7 to 47.8+
RBPMS-NTRK3	3	67 (9, 99)	3.3+ to 23.0
SQSTM1-NTRK1	3	67 (9, 99)	9.9 to 12.9+
EPS15-NTRK1	2	100 (16,100)	9.5 to 67.2
KANK1-NTRK3	2	0 [NC]	NA
MYO5A-NTRK3	2	100 (16, 100)	3.7+ to 12.5+
RBPMS-NTRK2	2	50 (1, 99)	27.1 ^b
SPECC1L-NTRK3	2	50 (1, 99)	19.1+ ^b
SQSTM1-NTRK3	2	50 (1, 99)	17.4+
ADAM10-NTRK3	1	0 [NC]	NA
AKAP13-NTRK3	1	0 [NC]	NA
AP3S2-NTRK3	1	0 [NC]	NA
ARHGEF11-NTRK1	1	0 [NC]	NA
ARID1A-NTRK1	1	0 [NC]	NA
ARNT2-NTRK3	1	0 [NC]	NA
ATP1A4-NTRK1	1	0 [NC]	NA
BCAN-NTRK1	1	100 [3, 100]	10.8 ^b
CAMSAP2-NTRK3	1	0 [NC]	NA
CD74-NTRK1	1	100 [3, 100]	3.7 ^b
CDC42BPB-NTRK3	1	0 [NC]	NA
CHTOP-NTRK1	1	100 [3, 100]	17.7+
CLIP1-NTRK1	1	100 [3, 100]	1.9+
CTNNA3-NTRK2 1	1	0 [NC]	NA
CTRC-NTRK1	1	0 [NC]	NA

<i>NTRK</i> Gene Fusion Partner	n	ORR^a % (95% CI)	DOR Range (months)
DDR2-NTRK1	1	0 [NC]	NA
DIAPH1-NTRK1	1	0 [NC]	NA
DLG2-NTRK2	1	0 [NC]	NA
DMXL2-NTRK3	1	0 [NC]	NA
FAM131B-NTRK3	1	0 [NC]	NA
FGFR1-NTRK3	1	0 [NC]	NA
GCOM1-NTRK3	1	0 [NC]	NA
GNAQ-NTRK2	1	0 [NC]	NA
GON4L-NTRK1	1	0 [NC]	NA
INTERGENIC REGION (UPSTREAM OF LIN28B)-NTRK3	1	0 [NC]	NA
IQGAP1-NTRK3	1	0 [NC]	NA
MTMR6-NTRK1	1	0 [NC]	NA
NFASC-NTRK1	1	0 [NC]	NA
NOS1AP-NTRK1	1	0 [NC]	NA
PDE4DIP-NTRK1	1	100 [3, 100]	3.6+ ^b
PHACTR1-NTRK3	1	0 [NC]	NA
PLEKHA6-NTRK1	1	0 [NC]	NA
PPL-NTRK1	1	100 [3, 100]	83.9+ ^b
PRDX1-NTRK1	1	100 [3, 100]	33.9 ^b
SCAMP1-NTRK3	1	0 [NC]	NA
SHC4-NTRK3	1	0 [NC]	NA
SLC28A3-NTRK2	1	0 [NC]	NA
STRN-NTRK2	1	100 [3, 100]	5.6 ^b
TCF4-NTRK1, UNC13B-NTRK3	1	0 [NC]	NA
TFG-NTRK3	1	100 [3, 100]	63.7+ ^b
TMEM245-NTRK2, ALAD-NTRK2	1	0 [NC]	NA
TMTC2-NTRK3	1	0 [NC]	NA
TNFSF15-NTRK1	1	0 [NC]	NA
TNS1-NTRK1	1	0 [NC]	NA
TP53-NTRK1	1	0 [NC]	NA
TPM3-NTRK1, DCST1-NTRK1, ZBTB7B-NTRK1, DCST2-NTRK1	1	100 [3, 100]	30.5+ ^b
TPM4-NTRK3	1	100 [3, 100]	25.6 ^b
TRAF2-NTRK2	1	0 [NC]	NA

NTRK Gene Fusion Partner	n	ORR^a % (95% CI)	DOR Range (months)
TRIM63-NTRK1	1	100 [3, 100]	1.9+ ^b
TRPM3-NTRK2	1	0 [NC]	NA
TRPM3-NTRK3	1	0 [NC]	NA
VTI1A-NTRK2, CHD2-NTRK2	1	0 [NC]	NA

NA: not available; NC: not calculated; + denotes ongoing

^a ORR according to RECIST 1.1

^b Based on a single subject

Patients with CNS Tumours

Sixty patients with primary CNS tumours and NTRK gene fusions were enrolled in study 2 (“NAVIGATE”) and in study 3 (“SCOUT”). Baseline characteristics for the 60 patients with primary CNS tumours with an NTRK gene fusion assessed by investigator were as follows: median age 9 years (range 0-79 years); 43 patients < 18 years of age and 17 patients ≥ 18 years, and 39 patients white and 28 patients male; and ECOG PS 0-1 (52 patients), or 2 (5 patients). Fifty seven (95%) CNS tumour patients had received prior cancer treatment (surgery, radiotherapy and/or previous systemic therapy). There was a median of 1 prior systemic treatment regimen received. Tumour responses for primary CNS tumours were assessed by the investigator using Response Assessment in Neuro Oncology (RANO) Criteria or Response Evaluation Criteria in Solid Tumours (RECIST v1.1).

Of the 60 patients with primary CNS tumours, confirmed response was observed in 21 patients (35%) with 5 of the 60 patients (8%) being complete responders and 16 (27%) being partial responders. At a median follow-up time of 15.7 months, the median duration of response was 17.2 months (2.8+ months, 70.9+ months). Further, 24 patients (40%) had stable disease. Thirteen patients (22%) had a progressive disease.

Disease control (including confirmed CR, pCR, PR, and SD of at least 16 weeks) was demonstrated in 41 of 60 patients, with a DCR of 68% (95% CI: [55, 80]).

16 Non-Clinical Toxicology

General toxicology

Repeated-dose toxicity was assessed in studies with daily oral administration up to 13-weeks in rats and monkey. Dose limiting skin lesions were only seen in rats and were primarily responsible for mortality and morbidity. In rats, severe toxicity was observed at doses corresponding to human AUC at the recommended clinical dose. Clinical signs of gastrointestinal toxicity including emesis, were dose limiting in monkeys. No relevant systemic toxicity were observed in monkeys at exposures which correspond to >10-times the human AUC at the recommended clinical dose.

Increased body weight, increased food consumption, and elevated serum liver enzymes (ALT and/or AST) are additional relevant findings that were observed in both species.

Genotoxicity

Larotrectinib was not mutagenic in bacterial reverse mutation (Ames) assays and in in vitro mammalian mutagenesis assays. Larotrectinib was negative in the *in vivo* mouse micronucleus test.

Carcinogenicity

Carcinogenicity studies have not been performed with larotrectinib.

Reproductive and developmental toxicology

Fertility

Fertility studies with larotrectinib have not been conducted. In 13-week repeated-dose studies, larotrectinib had no effects on spermatogenesis in rats and on the histopathology of male reproductive organs in rats and monkeys at doses corresponding to approximately 7-times (rats) and 10-times (monkeys) the human AUC at the recommended clinical dose.

In a 1-month study in female rats, fewer corpora lutea, increased incidence of anestrus and decreased uterine weight with uterine atrophy were observed at doses corresponding to approximately 8-times the human AUC at the recommended clinical dose; these effects were reversible. No effects on reproductive organs were seen in the 13-week study in rats and monkeys at doses corresponding to approximately 3 times (rats) and approximately 17-times (monkeys) the human AUC at the recommended clinical dose.

Embryo-fetal development

In embryo-fetal development studies where pregnant rats and rabbits were dosed with larotrectinib during the period of organogenesis, malformations were observed at maternal exposures that were approximately 9- and 0.6- times, respectively, those observed at the clinical dose of 100 mg twice daily. Larotrectinib was not embryotoxic up to maternally toxic doses. Larotrectinib crosses the placenta in both species and can be detected in blood samples obtained from fetuses at termination.

Juvenile toxicology

Larotrectinib was administered in a juvenile toxicity study in rats at twice daily doses of 0.2, 2 and 7.5 mg/kg from postnatal day (PND) 7 to 27 and at twice daily doses of 0.6, 6 and 22.5 mg/kg between PND 28 and 70. The dosing period was equivalent to human pediatric populations from newborn to adulthood. The lowest dose (0.2/0.6 mg/kg BID), equivalent to 0.02-fold the recommended clinical exposure, was considered the NOAEL. At doses $\geq 2/6$ mg/kg BID (0.5-fold the recommended clinical exposure), increased mortality, neuronal effects (increased incidence of partially closed eyelids, lower hindlimb grip strength and foot splay), decreased growth (shorter tibial length and lower body weight gain with lower food intake) and delay in sexual development were noted. At doses 7.5/22.5 mg/kg BID (3-fold the recommended clinical exposure), central nervous system-related signs including head flick and circling, increased escape time and number of errors in a maze swim test when the original path is reversed, skin lesions, and swollen abdomen (females) were noted. Lower fertility was noted in animals at 3-times the recommended clinical exposure.

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **VITRAKVI**®

Larotrectinib capsules

Larotrectinib oral solution

This Patient Medication Information is written for the person who will be taking **VITRAKVI**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This Patient Medication Information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **VITRAKVI**, talk to a healthcare professional.

What **VITRAKVI** is used for:

For the following indication **VITRAKVI** has been approved with conditions (NOC/c). This means it has passed Health Canada's review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the drug works the way it should. For more information, talk to your healthcare professional.

VITRAKVI is used in children (18 days old to 18 years old) and adults.

- It can treat solid tumours that have a Neurotropic Tyrosine Receptor Kinase (*NTRK*) gene fusion. The *NTRK* gene fusion should not have a known resistance mutation.
- It can treat cancers that have spread to different parts of the body, Or, cancers where removal is likely to cause serious problems.
- **VITRAKVI** is for patients without other treatment choices.

To benefit from **VITRAKVI**, the patient must have a tumour that has an *NTRK* gene fusion. This can be checked by a test that is done before you start **VITRAKVI**.

What is a Notice of Compliance with Conditions (NOC/c)?

A Notice of Compliance with Conditions (NOC/c) is a type of approval to sell a drug in Canada.

Health Canada only gives an NOC/c to a drug that treats, prevents, or helps identify a serious or life-threatening illness. The drug must show promising proof that it works well, is of high quality, and is reasonably safe. Also, the drug must either respond to a serious medical need in Canada, or be much safer than existing treatments.

Drug makers must agree in writing to clearly state on the label that the drug was given an NOC/c, to complete more testing to make sure the drug works the way it should, to actively monitor the drug's performance after it has been sold, and to report their findings to Health Canada.

How VITRAKVI works:

TRK fusion cancer always has a change in a gene called “Neurotrophic Tyrosine Receptor Kinase” (NTRK). The alteration in this gene causes the body to make a protein called “TRK fusion”. TRK fusion proteins can lead to uncontrolled cell growth and cancer.

VITRAKVI stops the TRK fusion proteins from working and may slow or stop the cancer from growing. It may also help to shrink the cancer.

The ingredients in VITRAKVI are:

Medicinal ingredient: larotrectinib (as larotrectinib sulfate)

Capsules

Non-medicinal ingredients: ammonia solution, dimethicone, FD&C Blue #2 aluminum lake, gelatin, propylene glycol, shellac, titanium dioxide.

Oral Solution

Non-medicinal ingredients: citric acid, hydroxypropyl betadex, purified water, sodium benzoate, sodium citrate, strawberry flavour, sucralose.

VITRAKVI comes in the following dosage forms:

Capsules: 25 mg and 100 mg

Oral solution: 20 mg/mL

Do not use VITRAKVI if:

- you are allergic to larotrectinib or any of the other ingredients of this medicine.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take VITRAKVI. Talk about any health conditions or problems you may have including if you:

- Have liver disease

Other warnings you should know about:

Take VITRAKVI only under the care of a doctor who knows how to use anti-cancer drugs.

Female Patients: Pregnancy and Breast-feeding Information

Talk to your healthcare provider before taking VITRAKVI if you are pregnant, may become pregnant or are breast-feeding.

- Avoid getting pregnant when on VITRAKVI. There may be a risk of harm or birth defects to the baby.
- Before starting on VITRAKVI, your doctor should make sure that you are not pregnant.
- Use effective birth control while taking VITRAKVI and for at least one month after the last dose. Ask your doctor about the best birth control method for you.

Tell your doctor right away if you become pregnant while taking VITRAKVI or in the first month after your last dose.

It is not known if VITRAKVI passes into breast milk. Do not breast-feed while taking VITRAKVI and for one week after the last dose.

Male Patients: Do not father a child while VITRAKVI is in your body

Avoid fathering a child by using effective birth control methods. Do this during treatment with VITRAKVI and for at least one month after the final dose.

Sodium benzoate: VITRAKVI oral solution contains 2 mg of sodium benzoate in each mL of oral solution. It may increase the risk of jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).

Driving and Using Machines

VITRAKVI may cause **Neurologic/Psychiatric Reactions**. This may make you feel dizzy or tired. It may affect your ability to walk and think clearly. If this happens, do not drive, cycle, or operate machinery. Wait until you know how you react to VITRAKVI before you do tasks which require special attention.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Some medicines can affect the level of VITRAKVI in your body. Also, VITRAKVI can affect the way some other medicines work. The medicines listed here may not be the only ones that could interact with VITRAKVI.

The following may interact with VITRAKVI:

- itraconazole, ketoconazole, posaconazole, voriconazole, and clarithromycin – used to treat fungal and bacterial infections
- atazanavir, nelfinavir, rifabutin, ritonavir, saquinavir, and efavirenz – used to treat HIV infection
- phenytoin, carbamazepine, phenobarbital – used to treat seizures
- St. John's wort – a herbal medicine, used to treat depression
- rifampin – used to treat bacterial infections
- cyclosporine, sirolimus, tacrolimus – used to prevent organ rejection in patients after transplantation
- quinidine – used to treat abnormal heart rhythms
- dihydroergotamine – used to treat migraine or cluster headache attack
- fentanyl – used for the treatment of chronic pain
- pimozide – an antipsychotic drug used to control motor or verbal tics

Avoid having grapefruit or its juice while on VITRAKVI. They may increase larotrectinib levels in your blood.

How to take VITRAKVI:

- Take exactly as prescribed for you by your healthcare provider. Continue to take VITRAKVI unless your healthcare provider tells you to stop. Treatment may continue as long as it is helpful to you.
- If you can't take it as prescribed, or you feel you do not need it anymore, contact your healthcare provider right away.
- The total daily dose is **usually** divided in two and given twice a day. Some **adults** may get a reduced dose prescribed once a day.

- Take with or without food.

VITRAKVI is available as a capsule or oral solution. The capsules and oral solution are interchangeable. Your doctor will prescribe the correct dose.

- To take a VITRAKVI dose by:
 - Capsule: swallow whole with water. Do NOT open, chew, or crush.
 - Oral solution: swallow it by mouth or take it through a feeding tube. Always use a dosing syringe to measure the dose. Ask your pharmacist where to get a suitable dosing syringe.

Usual dose:

Depends on if you are a child or an adult. Your healthcare professional will monitor your condition. Your doctor may interrupt, reduce, increase, or stop your dose. This may occur based on your current health, if you have liver disease, take other medications, if your disease gets worse, or if you have too many side effects.

Child Usual Daily Dose:

Your child's healthcare provider will work out the right daily dose in milligrams for your child. It is based on the child's height and weight. The daily prescribed amount is then divided in two and given twice a day. They can take:

- Capsule(s): by mouth.
or
- Oral Solution: by mouth or through a feeding tube.

Adult (from 18 years old) Usual Daily Dose 200 mg:

- Capsule(s) 100 mg by mouth twice a day.
or
- Oral Solution: 5 mL (100 mg) twice a day by mouth or through a feeding tube.

Child and Adult **Maximum Daily Dose 200 mg:** 100 mg twice a day from capsules or the oral solution.

Overdose:

If you think you, or a person you are caring for, have taken too much VITRAKVI, contact a healthcare professional, hospital emergency department, or regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

If you miss a dose, take your next dose at the usual time. Do not take a double dose to make up for a missed dose.

If you or your child vomits (are sick) after taking VITRAKVI, just take the next dose at the usual time.

Possible side effects from using VITRAKVI:

These are not all the possible side effects you may feel when taking VITRAKVI. If you experience any side effects not listed here, contact your healthcare professional.

Side effects may include:

- feeling tired or weak
- headache
- fever
- nausea, vomiting, constipation, diarrhea
- cough, shortness of breath, stuffy nose
- swelling or pain of arms, legs, hands, or feet
- muscle weakness
- muscle, joints, abdominal, or back pain
- decreased appetite
- taste changes
- weight gain
- rash
- high blood pressure

VITRAKVI can cause abnormal physical exam and blood test results. Your doctor will do some tests before, during and after your treatment. These tests include checking for **Neurologic/Psychiatric Reactions** and any **Liver Problems**. The doctor will interpret the results. They will tell you if there are any abnormalities in your tests that might need treatment.

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Very common			
Anaemia (reduction in the number of red blood cells): Feel tired, looking pale and you may feel your heart pumping		✓	
Decreased Neutrophils and Leukocytes (white blood cells): Fever, fatigue, mouth ulcer, sore throat, or infections.		✓	
Liver Problems and increased liver enzymes: Loss of appetite, feeling sick or being sick, yellow skin, itching or pain in your liver area		✓	
Neurologic/Psychiatric Reactions including: • Encephalopathy: Changes to the brain that cause problems		✓	

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
with brain functioning. Delirium and memory impairment. • Gait disturbance: Difficulty walking normally, balance disorder. • Loss of consciousness, mental status change, tremor. • Anxiety • Paraesthesia: Abnormal sense of touch or tingling, burning feeling in your hands and feet.			
Dizziness	✓		
Common			
Sepsis (serious infection due to bacteria in your blood): High fever, shaking, chills, weakness Fast heart rate. Rapid breathing.			✓
Symptoms of decreased platelets (cells that help you form blood clots): bruise or bleed easily		✓	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- For capsules:
 - Store at room temperature 15 to 30°C.
- For oral solution
 - Store at 2°C to 8°C. Keep refrigerated. Do not freeze.
 - Discard 30 days after first opening.
- Keep out of reach and sight of children.
- Do not use this medicine after the expiry date which is stated on the carton and the bottle label after "EXP". The expiry date refers to the last day of that month.
- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

If you want more information about VITRAKVI:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada Drug Product Database website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website <http://www.bayer.ca>; or by calling Bayer Medical Information at 1-800-265-7382 or canada.medinfo@bayer.com.

This leaflet was prepared by:



Bayer Inc.
2920 Matheson Blvd East
Mississauga, Ontario
L4W 5R6
Canada

Date of Authorization: 2026-08-26

© 2026, Bayer Inc.

® TM see www.bayer.ca/tm-mc